secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2023-10-05T23:59:59+00:00
Accession:  0001013762-23-002136
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell Q3 preliminary sales $5.4M (+13% YoY); backlog rises to $8.9M
----------------------------------------------------------------------

- Q3 2023 total sales $5.40M, up 13% from $4.80M in Q3 2022.
- Nine-month sales $12.38M, down 16% YoY; trailing twelve months $16.29M, down 19%.
- Finished goods production in Q3 was $5.3M, approximately 89% of the $6M quarterly goal.
- Order backlog increased to $8.9M from $8M at June 30, 2023 and $2.5M at Dec 31, 2022.
- Company overcame earlier contamination events; third FDA submission for Re-Tain under 6-month review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000101376223002136/0001013762-23-002136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000101376223002136/ea186386-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001013762-23-002136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer